201 related articles for article (PubMed ID: 28645428)
1. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R; van Meurs HS; Rutten MJ; Naaktgeboren CA; Opmeer BC; Gaarenstroom KN; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HWR; Arts HJG; Zusterzeel PLM; Pijnenborg JMA; van Haaften M; Engelen MJA; Boss EA; Vos MC; Gerestein KG; Schutter EMJ; Kenter GG; Bossuyt PMM; Mol BW; Buist MR
Gynecol Oncol; 2017 Sep; 146(3):449-456. PubMed ID: 28645428
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
3. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
Rutten MJ; van Meurs HS; van de Vrie R; Gaarenstroom KN; Naaktgeboren CA; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HW; Arts HJ; Zusterzeel PL; Pijnenborg JM; van Haaften M; Fons G; Engelen MJ; Boss EA; Vos MC; Gerestein KG; Schutter EM; Opmeer BC; Spijkerboer AM; Bossuyt PM; Mol BW; Kenter GG; Buist MR
J Clin Oncol; 2017 Feb; 35(6):613-621. PubMed ID: 28029317
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
6. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
8. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.
Rutten MJ; Gaarenstroom KN; Van Gorp T; van Meurs HS; Arts HJ; Bossuyt PM; Ter Brugge HG; Hermans RH; Opmeer BC; Pijnenborg JM; Schreuder HW; Schutter EM; Spijkerboer AM; Wensveen CW; Zusterzeel P; Mol BW; Kenter GG; Buist MR
BMC Cancer; 2012 Jan; 12():31. PubMed ID: 22264278
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Harrison RF; Cantor SB; Sun CC; Villanueva M; Westin SN; Fleming ND; Toumazis I; Sood AK; Lu KH; Meyer LA
Gynecol Oncol; 2021 Apr; 161(1):56-62. PubMed ID: 33536126
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
Lim SL; Havrilesky LJ; Habib AS; Secord AA
Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
12. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
13. [PRIMARY CYTOREDUCTIVE SURGERY VERSUS NEOADJUVANT CHEMOTHERARY IN TREATMENT OF ADVANCED OVARIAN CANCER (STAGE III C-IV). OUR AND FOREIGN EXPERIENCE].
Ivanov S; Kovachev E; Kolev N; Bechev B; Kolev N
Akush Ginekol (Sofiia); 2016; 55 Suppl 1 Pt 1():16-9. PubMed ID: 27514164
[TBL] [Abstract][Full Text] [Related]
14. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.
Gómez-Hidalgo NR; Martinez-Cannon BA; Nick AM; Lu KH; Sood AK; Coleman RL; Ramirez PT
Gynecol Oncol; 2015 Jun; 137(3):553-8. PubMed ID: 25827290
[TBL] [Abstract][Full Text] [Related]
15. Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim YT; Kim S
J Gynecol Oncol; 2023 Mar; 34(2):e17. PubMed ID: 36562129
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and periampullary cancer.
Morris S; Gurusamy KS; Sheringham J; Davidson BR
BMC Gastroenterol; 2015 Apr; 15():44. PubMed ID: 25888495
[TBL] [Abstract][Full Text] [Related]
17. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
18. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
Chesnais M; Lecuru F; Mimouni M; Ngo C; Fauconnier A; Huchon C
PLoS One; 2017; 12(11):e0187245. PubMed ID: 29117194
[TBL] [Abstract][Full Text] [Related]
19. Is complete cytoreductive surgery feasible in this patient with ovarian cancer?
Dessapt AL; Huchon C; Ngo C; Bats AS; Bensaid C; Lecuru F
Surg Oncol; 2016 Sep; 25(3):326-31. PubMed ID: 27566040
[TBL] [Abstract][Full Text] [Related]
20. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
